Get all your news in one place.
100's of premium titles.
One app.
Start reading
Medical Daily
Medical Daily
World
Suneeta Sunny

What Is Kisunla? Know All About New FDA-Approved Drug For Alzheimer's Disease

In a trial conducted among more than 1,700 participants, Kisunla slowed cognitive and functional decline by up to 35% compared to placebo. (Credit: Image by Freepik)

A groundbreaking advancement in Alzheimer's treatment offers new hope, as the U.S. Food and Drug Administration (FDA) has approved Donanemab, a drug marketed as Kisunla, for individuals in the early stages of the disease.

Kisunla manufactured by Eli Lilly could significantly slow cognitive decline in people with early symptomatic Alzheimer's disease, according to results of the company's clinical trials.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.